Allurion Unveils Promising Results: Combining Allurion Program with Low-Dose GLP-1 Boosts Weight Loss and Muscle Mass

March 21, 2025

DENVER, Colo., Mar 21, 2025 (247marketnews.com)- Allurion Technologies (NYSE:ALUR) revealed initial findings from a groundbreaking case series blending its Allurion Program with low-dose GLP-1 therapy.

An impressive 20.3% average total body weight loss paired with a 15% increase in lean body mass after eight months, alongside perfect adherence to GLP-1 medication, a potential game-changer for sustainable, muscle-preserving weight loss.

In this study, 52 patients kicked off with the Allurion Balloon, then started 0.25 mg semaglutide after one month. Over the next six months, doses rose to a maximum of 1.0 mg, well below the typical 2.4 mg ceiling. By month eight, patients shed 20.3% of their body weight on average, while lean mass climbed from 59.6% to 68.5% of total body composition. Remarkably, all 52 stuck with the GLP-1 regimen, defying the high dropout rates plaguing standalone GLP-1 treatments.

Dr. Luigi Flagiello, bariatric surgeon at Clinica Ruesch overseeing the series, sees a clear edge. “I believe combining the Allurion Balloon with low-dose GLP-1 therapy has several advantages. These results indicate that a combination approach increases weight loss and that by using lower doses of GLP-1s, patients do not experience as many side effects—including muscle wasting—and have improved adherence. Patients may also be benefiting from two distinct physiological impacts: satiety induction from the balloon and reduced hunger from the GLP-1.”

This contrasts starkly with prior studies, where GLP-1 therapy alone slashed lean mass by 40% of weight lost and saw 30% of patients quit within a month, with 58% dropping out before meaningful benefits due to side effects and cost (references from Obesity Week 2024 and JAMA studies).

Dr. Shantanu Gaur, Allurion’s Founder and CEO, added, “Muscle wasting and lack of adherence are significant challenges for GLP-1s, and this initial data suggests that a combination approach that leverages Allurion’s full program—which includes the balloon, our Virtual Care Suite, and our behavior change program—may be a compelling solution. We plan on building upon this promising initial data and are optimistic that this could become a new standard of care for patients who want metabolically healthy weight loss.”

With a $30 billion obesity treatment market in sight, Allurion is collecting more data for upcoming medical conferences.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (ALUR)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.